Product
VOY-101
2 clinical trials
3 indications
Indication
Age-related macular degenerationIndication
Macular DegenerationIndication
Geographic AtrophyClinical trial
Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non- Neovascular Age-Related Macular DegenerationStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular DegenerationStatus: Active (not recruiting), Estimated PCD: 2025-11-01